3-(piperidin-1-ylmethyl)pyridine | 13552-35-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-(piperidin-1-ylmethyl)pyridine
• 英文别名: 3-piperidin-1-ylmethyl-pyridine
• CAS: 13552-35-7
• 化学式: C₁₁H₁₆N₂
• 分子量: 176.261
• InChiKey: ZAHGBBWQTOLMRX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  16.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  piperidin-1-yl(pyridin-3-yl)methanone 在 四氯化钛 、 magnesium 作用下， 以 四氢呋喃 为溶剂， 以74%的产率得到3-(piperidin-1-ylmethyl)pyridine
  参考文献：
  名称：

  方便，通用地将酰胺还原为低价钛的胺

  摘要：

  AbstractLow‐valent titanium readily prepared in situ from TiCl4 and Mg powder in THF is found to be an active agent for the reduction of amides which were previously considered to be inert towards low‐valent titanium. The reaction proceeds under very mild conditions, and is applicable to all types of amides, primary, secondary and tertiary, to produce the corresponding amines in good to excellent yields. This new finding provides a practical, convenient and general method for the important transformation of amides to amines. A plausible reaction mechanism is proposed.magnified image

  DOI：

  10.1002/adsc.201300355

文献信息

• [EN] PIPERIDINES OR PIPERIDONES SUBSTITUTED WITH UREA AND PHENYL<br/>[FR] PIPÉRIDINES OU PIPÉRIDONES SUBSTITUÉES PAR DE L'URÉE ET DU PHÉNYLE
  申请人：GRUENENTHAL GMBH

  公开号：WO2019170904A1

  公开（公告）日：2019-09-12

  The present invention relates to a compound according to general formula (I) which acts as a modulator of FPR2 and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by FPR2.

  本发明涉及一种符合一般式（I）的化合物，该化合物作为FPR2的调节剂，并可用于治疗和/或预防至少部分由FPR2介导的疾病。
• [EN] AMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] DERIVES AMIDIQUES INHIBITEURS DE L'HISTONE DEACETYLASE
  申请人：ANGELETTI P IST RICHERCHE BIO

  公开号：WO2006005941A1

  公开（公告）日：2006-01-19

  The present invention relates to ketone derivatives that are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are useful for treating cellular proliferative diseases, including cancer. Further, the compounds of the present invention are useful for treating neurodegenerative diseases, schizophrenia and stroke among other diseases.

  本发明涉及一种抑制组蛋白去乙酰化酶（HDAC）的酮衍生物。本发明的化合物对治疗细胞增殖性疾病，包括癌症，具有用处。此外，本发明的化合物对治疗神经退行性疾病、精神分裂症和中风等疾病也具有用处。
• Scope of Aminomethylations via Suzuki−Miyaura Cross-Coupling of Organotrifluoroborates
  作者：Gary A. Molander、Paul E. Gormisky、Deidre L. Sandrock

  DOI：10.1021/jo800183q

  日期：2008.3.1

  previously reported the Suzuki−Miyaura reaction of N,N-dialkylaminomethyltrifluoroborates with aryl bromides. Herein, we report a further investigation of the scope and limitations of this palladium-catalyzed aminomethylation reaction. Aryl chlorides, iodides, and triflates coupled in good to excellent yields to give N,N-dialkylbenzylic amines. The aminomethylation of alkenyl bromides was also examined.

  我们先前报道了N，N-二烷基氨基甲基三氟硼酸酯与芳基溴化物的Suzuki-Miyaura反应。本文中，我们报告了对该钯催化的氨基甲基化反应的范围和局限性的进一步研究。芳基氯化物，碘化物和三氟甲磺酸酯以良好至优异的收率偶联，得到N，N-二烷基苄基胺。还检查了烯基溴化物的氨基甲基化。
• [EN] NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES AZOTÉS ET LEUR APPLICATION DANS DES MÉDICAMENTS
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2015090232A1

  公开（公告）日：2015-06-25

  The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, IPF, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

  本发明涉及医学领域，提供了新颖的含氮杂环化合物，其制备方法以及作为药物的用途，特别是用于治疗和预防组织纤维化。本文还提供了包含这些含氮杂环化合物的药用可接受组合物，以及这些组合物在治疗人类或动物组织纤维化方面的用途，特别是用于人类或动物肾间质纤维化、肾小球硬化、肝纤维化、肺纤维化、IPF、腹膜纤维化、心肌纤维化、皮肤纤维化、术后粘连、良性前列腺增生、骨骼肌纤维化、硬皮病、多发性硬化、胰腺纤维化、肝硬化、肌肉肉瘤、神经纤维瘤、肺间质纤维化、糖尿病肾病、阿尔茨海默病或血管纤维化。
• [EN] NOVEL SELECTIVE DELTA-OPIOID RECEPTOR AGONISTS USEFUL FOR THE TREATMENT OF PAIN, ANXIETY AND DEPRESSION.<br/>[FR] NOUVEAUX AGONISTES DES RÉCEPTEURS OPIACÉS DELTA SÉLECTIFS UTILES POUR LE TRAITEMENT DE LA DOULEUR, DE L'ANXIÉTÉ ET DE LA DÉPRESSION
  申请人：PHARMNOVO AB

  公开号：WO2016099394A1

  公开（公告）日：2016-06-23

  A compound of formula I, For use in pain therapy and a pharmaceutical composition comprising said compound.

  一种化学式I的化合物，用于疼痛治疗，以及包括该化合物的药物组合物。